Intra-Cellular Therapies is an American biotechnology company focused on developing new therapeutic options for the treatment of neuropsychiatric disorders, including schizophrenia, bipolar disorder, and other mental health conditions. The company employs advanced technologies focused on cellular signaling and neurobiology to create innovative drugs that target specific molecular pathways in the brain. Intra-Cellular Therapies is known for its research in neurology and psychiatry, aiming to improve the lives of patients suffering from these challenging diseases.
💡 Johnson & Johnson: $14.6 billion acquisition strengthens the pharmaceutical giant's position in the neurological drugs market 💊
Johnson & Johnson $JNJ, one of the biggest players in the healthcare industry, has once again shown that growth through strategic acquisitions is their forte.
The company announced last week the purchase of biopharmaceutical firm Intra-Cellular... Read more
It's not a bad business, but I'd rather buy something riskier. Plus this stock isn't growing as mentioned and I don't see why it should start growing.